Oncology Clinical Trial Finder
Breast Cancer

Active, not recruiting • Phase I, II • Stage III, IV • Medical Oncology • Post-Menopausal • Interventional

The following is imported from ClinicalTrials.gov:

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose as a monotherapy and in combination with chemotherapy for evaluation in these patients.

Breast Cancer

Study Design
Study type:


Estimated enrollment:

170 participant

Actual study start date:

October 9, 2019

Eligibility Criteria
Ages eligible for study:

18 - 999

Sexes eligible for study:


Arms and Intervention
  • CYT-0851

  • CYT-0851 in combination with gemcitabine

  • CYT-0851 in combination with capecitabine

  • CYT-0851 in combination with rituximab and bendamustine

Trial Information at Site
Last Updated:
Trial Information
ClinicalTrial.gov ID:

Active, not recruiting

Estimated Enrollment:


Last Updated:


Principal Investigator

Markus Renschler, MD

Trial Sponsor

Cyteir Therapeutics, Inc.

Study Location (21)

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Mayo Clinic

Rochester, Minnesota, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States


© 2024 Outcomes4Me Inc. All rights reserved.